Qiagen agreed to acquire Parse Biosciences for $225 million in cash plus up to $55 million in milestones, folding an instrument‑free single‑cell sample prep technology into Qiagen’s sample and informatics portfolio. Qiagen cited scale and cross‑sell potential to its installed base of laboratories, and said the deal accelerates its entry into the expanding single‑cell market. The acquisition reflects consolidation as established life‑science vendors buy specialized sample‑prep and single‑cell tools to secure end‑to‑end genomics workflows.